Effect of hyperthermia and proton beam radiation as a novel approach in chordoma cells death and its clinical implication to treat chordoma. (2nd December 2021)

• Record Type: Journal Article
• Authors: Singh, Prerna; Eley, John; Saeed, Ali; Bhandary, Binny; Mahmood, Nayab; Chen, Minjie; Dukic, Tijana; Mossahebi, Sina; Rodrigues, Dario B.; Mahmood, Javed; Vujaskovic, Zeljko; Shukla, Hem D.
• Is Part Of: International journal of radiation biology. Volume 97:Number 12(2021)
• Page Start: 1675
• Page End: 1686
• Publication Date: 2021-12-02
• Subjects: Chordoma -- sacral chordoma -- radiation-resistant -- hyperthermia -- radiosensitizer -- proton beam radiation therapy; Radiation -- Physiological effect -- Periodicals; Radiobiology -- Periodicals; 571.45
• DOI: 10.1080/09553002.2021.1976861
• Languages: English
• ISSNs: 0955-3002

Abstract

Abstract: Purpose: Chordoma is a locally aggressive tumor that most commonly affects the base of the skull/clivus, cervical, and sacral spine. Conventional radiotherapy (RT), cannot be safely increased further to improve disease control due to the risk of toxicity to the surrounding critical structures. Tumor-targeted hyperthermia (HT) combined with Proton Beam Radiation Therapy (PBRT) is known to act as a potent radiosensitizer in cancer control. In this study, we investigated whether PBRT efficacy for chordoma can be enhanced in combination with HT as a radiosensitizer. Material and methods: Human chordoma cell lines, U-CH2 and Mug-chor1 were treated in vitro with HT followed by PBRT with variable doses. The colony-forming assay was performed, and dose-response was characterized by linear-quadratic model fits. HSP-70 and Brachyury (TBXT) biomarkers for chordoma aggression levels were quantified by western blot analysis. Gene microarray analysis was performed by U133 Arrays. Pathway Analysis was also performed using IPA bioinformatic software. Results: Our findings in both U-CH2 and Mug–Chor1 cell lines demonstrate that hyperthermia followed by PBRT has an enhanced cell killing effect when compared with PBRT-alone ( p < .01). Western blot analysis showed HT decreased the expression of Brachyury protein ( p < .05), which is considered a biomarker for chordoma tumor aggression. HT with PBRT also exhibited an RT-dose-dependent decrease of Brachyury expression ( p < .05). We also observed enhanced HSP-70 expression due to HT, RT, and HT + RT combined in both cell lines. Interestingly, genomic data showed 344 genes expressed by the treatment of HT + RT compared to HT (68 genes) or RT (112 genes) as individual treatment. We also identified activation of death receptor and apoptotic pathway in HT + RT treated cells. Conclusion: We found that Hyperthermia (HT) combined with Proton Beam Radiation (PBRT) could significantly increase chordoma cell death by activating the death receptor pathway and apoptosis which has the promise to treat metastatic chordoma.